134 related articles for article (PubMed ID: 11821445)
1. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
[TBL] [Abstract][Full Text] [Related]
2. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Giles FJ; Feldman EJ; Roboz GJ; Larson RA; Mamus SW; Cortes JE; Verstovsek S; Faderl S; Talpaz M; Beran M; Albitar M; O'Brien SM; Kantarjian HM
Leuk Res; 2003 Dec; 27(12):1091-6. PubMed ID: 12921945
[TBL] [Abstract][Full Text] [Related]
5. Troxacitabine activity in extramedullary myeloid leukemia.
Alvarado Y; Kantarjian HM; Cortes JE; Apostolidou E; Bivins C; Giles FJ
Hematology; 2002 Jun; 7(3):179-85. PubMed ID: 12243982
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
8. Troxacitabine-based therapy of refractory leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):261-6. PubMed ID: 12113049
[TBL] [Abstract][Full Text] [Related]
9. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F
Leuk Lymphoma; 2007 Jan; 48(1):39-45. PubMed ID: 17325846
[TBL] [Abstract][Full Text] [Related]
10. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.
Dent SF; Arnold A; Stewart DJ; Gertler S; Ayoub J; Batist G; Goss G; Nevile A; Soulieres D; Jolivet J; McLntosh L; Seymour L
Lung; 2005; 183(4):265-72. PubMed ID: 16211462
[TBL] [Abstract][Full Text] [Related]
13. Troxacitabine: BCH 4556, SPD 758, Troxatyl.
Adis International Ltd
Drugs R D; 2003; 4(4):264-8. PubMed ID: 12848594
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Investig Drugs; 2007 Apr; 16(4):547-57. PubMed ID: 17371201
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.
Lapointe R; Létourneau R; Steward W; Hawkins RE; Batist G; Vincent M; Whittom R; Eatock M; Jolivet J; Moore M
Ann Oncol; 2005 Feb; 16(2):289-93. PubMed ID: 15668286
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
[TBL] [Abstract][Full Text] [Related]
18. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Giles FJ; Kantarjian HM; Cortes JE; Garcia-Manero G; Verstovsek S; Faderl S; Thomas DA; Ferrajoli A; O'Brien S; Wathen JK; Xiao LC; Berry DA; Estey EH
J Clin Oncol; 2003 May; 21(9):1722-7. PubMed ID: 12721247
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Bélanger K; Moore M; Baker SD; Dionne J; Maclean M; Jolivet J; Siu L; Soulières D; Wainman N; Seymour L
J Clin Oncol; 2002 May; 20(10):2567-74. PubMed ID: 12011137
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
